Literature DB >> 2366179

Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat.

F M Belpaire1, F de Smet, L J Vynckier, A M Vermeulen, M T Rosseel, M G Bogaert, L Chauvelot-Moachon.   

Abstract

The pharmacokinetics of three beta adrenoceptor blocking drugs atenolol, metoprolol, propranolol and of the model drug antipyrine were studied in 3-, 12- and 24-month-old rats. Alpha-1-acid glycoprotein in plasma was slightly increased and the free fraction of propranolol was slightly decreased in the 24-month-old rats. For the four drugs studied, the volume of distribution and the clearance were decreased in the older rats. For propranolol, metoprolol and antipyrine these decreases were already observed in 12-month-old rats, for atenolol only in the 24-month-old rats. There was no change in half-life as a function of age for the three beta blockers; for antipyrine a significant increase in half-life was seen. The decreased volume of distribution suggests a lower tissue binding or a decrease in total body fluid. The change in clearance in function of age can probably be explained for metoprolol and propranolol by a decrease in hepatic blood flow as no change in metabolism or protein binding occurs, for atenolol by a decrease in renal function and for antipyrine by a decrease in metabolism. After p.o. administration of the beta blockers, no significant increase in area under the plasma drug concentration-time curve was observed for propranolol and metoprolol as a function of age, but for atenolol, a significant increase in area under the plasma drug concentration-time curve was seen in the 24-month-old rats, due to a decrease in renal function, as bioavailability of atenolol did not change in function of age.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2366179

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Continuous blood withdrawal as a rapid screening method for determining clearance of oral bioavailability in rats.

Authors:  W G Humphreys; M T Obermeier; R A Morrison
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

2.  The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens.

Authors:  Gary W Caldwell; David M Ritchie; John A Masucci; William Hageman; Carlos Cotto; Jeffrey Hall; Becki Hasting; William Jones
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

3.  Stress can affect drug pharmacokinetics via serum/tissues protein binding and blood flow rate alterations.

Authors:  Kotsiou Antonia; Alevizou Anastasia; Christine Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-12-16       Impact factor: 2.441

4.  Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.

Authors:  Yeamin Huh; David E Smith; Meihau Rose Feng
Journal:  Xenobiotica       Date:  2011-09-05       Impact factor: 1.908

5.  Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.

Authors:  N Snelder; B A Ploeger; O Luttringer; D F Rigel; F Fu; M Beil; D R Stanski; M Danhof
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

6.  Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.

Authors:  Laura Letendre; Mark Scott; Glenn Dobson; Ismael Hidalgo; Bruce Aungst
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

7.  Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone.

Authors:  Dennis D Rasmussen; Lauren E Beckwith; Carrie L Kincaid; Janice C Froehlich
Journal:  Alcohol Clin Exp Res       Date:  2014-05-30       Impact factor: 3.455

8.  Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.

Authors:  T J van Steeg; J Freijer; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-10       Impact factor: 8.739

Review 9.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

Review 10.  Scaling basic toxicokinetic parameters from rat to man.

Authors:  K Bachmann; D Pardoe; D White
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.